Overview
Description
Hikma Pharmaceuticals PLC is a publicly traded multinational pharmaceutical manufacturer that specializes in producing generic, specialty, and branded medicines for global markets. The company's core business encompasses the development, manufacturing, and distribution of a diverse portfolio of pharmaceutical products, with an emphasis on non-branded generics and in-licensed medicines. Hikma operates across three primary segments: injectables, generics, and branded pharmaceuticals, with a significant portion of its revenue driven by the supply of generic injectables to hospitals, particularly in North America, which is its largest market. Additional operations span the Middle East and North Africa, the United Kingdom, and various European regions. Founded in 1978, Hikma has established a robust international presence, owning manufacturing plants and R&D centers in several countries. The firm’s strategic focus on expanding access to affordable medicines underscores its commitment to public health and its influential role as a leading supplier in key regions such as MENA and the US. Hikma’s position as a FTSE 100 constituent illustrates its relevance and stability within the global healthcare industry.
About
CEO
Mr. Riad Ali Mishlawi
Employees
9500
Address
1 New Burlington Place
London, W1S 2HR
London, W1S 2HR
Phone
44 20 7399 2760
Website
Instrument type
Common stock
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
Germany
MIC code
XBER